AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%. The ...
By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...
The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets ...
AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and ...
Newsable Asianet News on MSN
AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know
AstraZeneca will use insitro’s AI platform to identify potential drug targets for MASH and cardiomyopathies, drawing on its ...
Asianet Newsable on MSN
Stocktwits biotech dealmaker: Gilead, AstraZeneca and Roche chase pipeline expansion over buyouts
Deals for AI discovery platforms and differentiated experimental candidates for obesity and solid tumors dominated the week.
AstraZeneca agrees a $40m upfront deal with insitro to use AI in drug discovery for MASH and cardiomyopathies. Read more.
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...
AstraZeneca Plc is collaborating with machine learning biotech Insitro Inc. in a deal worth as much as $1.86 billion intended ...
AstraZeneca has partnered with AI biotech insitro to identify drug targets and develop potential treatments for MASH, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results